DRMA.JK(DRMA.JK)
DRMA.JK
No analyst ratings available
No analyst price targets available for DRMA.JK
Analyst coverage may not be available for this symbol
Earnings surprise history unavailable.
No recent analyst actions
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $6.91T | $7.50T | $7.39T |
| Low | $6.85T | $7.37T | $7.30T |
| High | $7.00T | $7.63T | $7.51T |
| EBITDA Avg | $1.14T | $1.23T | $1.22T |
| Low | $1.13T | $1.21T | $1.20T |
| High | $1.15T | $1.25T | $1.23T |
| EBIT Avg | $919.90B | $999.33B | $984.61B |
| Low | $912.70B | $981.35B | $971.68B |
| High | $932.54B | $1.02T | $1.00T |
| Net Income Avg | $757.19B | $835.20B | $781.10B |
| Low | $736.42B | $804.76B | $767.84B |
| High | $777.97B | $865.64B | $797.09B |
| EPS Avg | $159.51 | $179.22 | $166.00 |
| Low | $156.49 | $171.01 | $163.17 |
| High | $165.32 | $183.95 | $169.38 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 | 1 / 1 |
| Metric | Q2 2026 |
|---|---|
| Revenue Avg | $1.55T |
| Low | $1.55T |
| High | $1.55T |
| EBITDA Avg | $254.38B |
| Low | $254.38B |
| High | $254.38B |
| EBIT Avg | $206.09B |
| Low | $206.09B |
| High | $206.09B |
| Net Income Avg | — |
| Low | — |
| High | — |
| EPS Avg | — |
| Low | — |
| High | — |
| Analysts (Rev / EPS) | 1 / — |